Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus Brevis Cgmcc 21249

Also known as: L. brevis CGMCC 21249, Lactobacillus brevis, Lactobacillus brevis CGMCC 21249

Overview

Lactobacillus brevis CGMCC 21249 is a specific strain of Gram-positive, facultative anaerobic probiotic bacterium. It is naturally found in fermented foods, the human gut, and the oral cavity. This particular strain is registered with the China General Microbiological Culture Collection Center (CGMCC) and is utilized in probiotic formulations. Its primary applications are centered around modulating gut microbiota, enhancing mucosal barrier function, and exhibiting potential anti-inflammatory effects. While research on *L. brevis* strains in general is moderately mature, with supporting in vitro and animal studies, clinical evidence specifically for the CGMCC 21249 strain is limited. The overall evidence quality for *L. brevis* effects is supported by mechanistic and some clinical studies, but strain-specific randomized controlled trials (RCTs) for CGMCC 21249 are scarce.

Benefits

The primary benefits of *Lactobacillus brevis* CGMCC 21249, extrapolated from studies on related strains, include immunomodulation and enhancement of gut barrier integrity. Certain *L. brevis* strains have been shown to reduce pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increase anti-inflammatory IL-10, suggesting potential benefits in inflammatory bowel disease (IBD) models. This immunomodulatory effect is supported by in vitro co-culture models. Furthermore, enhancement of tight junction proteins (ZO-1, Occludin, E-cadherin) has been observed in vitro, indicating support for mucosal barrier maintenance. Secondary benefits include strong acid resistance and survival in gastrointestinal conditions, partly due to glutamate decarboxylase activity, which aids in acid tolerance and persistence in the gut. There are also preliminary indications of oral health benefits through modulation of oral biofilms, though this is highly strain-dependent and not specific to CGMCC 21249. While potentially beneficial for individuals with IBD or gut barrier dysfunction, clinical data on CGMCC 21249 are currently lacking. Quantitative effect sizes are not well established for this specific strain, and while related *L. brevis* strains show statistically significant cytokine modulation in vitro, clinical validation is needed.

How it works

*Lactobacillus brevis* CGMCC 21249 exerts its effects primarily through immunomodulation and gut barrier enhancement. It modulates the immune response by downregulating pro-inflammatory cytokines and upregulating anti-inflammatory cytokines, as observed in related strains. The bacterium also enhances epithelial barrier function by upregulating tight junction proteins, thereby maintaining mucosal integrity. A key survival mechanism is its acid tolerance, facilitated by the glutamate decarboxylase (GAD) system, which converts glutamate to GABA, enabling the bacterium to survive in acidic environments like the stomach. As a live microorganism, its efficacy relies on its ability to survive passage through the gastrointestinal tract. It is believed to interact with the host's gut microbiota and immune cells to produce its probiotic effects.

Side effects

*Lactobacillus brevis* CGMCC 21249 is generally regarded as safe (GRAS) for probiotic use, consistent with *L. brevis* species commonly found in fermented foods. No significant adverse effects have been reported in high-quality studies. Mild gastrointestinal symptoms, such as bloating or gas, are theoretically possible but are uncommon. There are no known serious drug interactions or contraindications associated with this strain. However, individuals in special populations, particularly those who are immunocompromised, should use probiotics cautiously due to a theoretical, albeit rare, risk of bacteremia. It is always advisable for such individuals to consult a healthcare professional before initiating probiotic supplementation.

Dosage

Specific dosing guidelines for *Lactobacillus brevis* CGMCC 21249 are not well established in the scientific literature. However, typical probiotic doses for *Lactobacillus* species in clinical studies generally range from 10^8 to 10^10 Colony Forming Units (CFU) per day. The optimal dosage can vary depending on the specific formulation and the targeted health condition. Crucially, the survival of the bacteria through the gastrointestinal tract is paramount for efficacy. There is no defined maximum safe dose, as probiotic supplements are generally well tolerated even at higher concentrations. It is often recommended to take probiotics with meals to enhance their survival through the digestive system. No specific cofactors have been identified that are necessary to enhance the efficacy of this strain.

FAQs

Is *L. brevis* CGMCC 21249 effective for gut health?

Evidence from related *L. brevis* strains suggests potential benefits for gut health, including immunomodulation and barrier integrity. However, specific clinical trials on CGMCC 21249 are currently lacking.

Is *L. brevis* CGMCC 21249 safe to use?

Yes, it is generally considered safe with minimal side effects reported. It belongs to a species commonly found in fermented foods and is regarded as safe for probiotic use.

How long does it take to see effects from *L. brevis* CGMCC 21249?

Based on studies of related probiotic strains, effects are typically observed after several weeks of consistent use. Individual responses may vary.

Can *L. brevis* CGMCC 21249 replace medication?

No, probiotics like *L. brevis* CGMCC 21249 are considered adjuncts to medical treatment and should not be used as replacements for prescribed medications or therapies.

Does pasteurization affect the efficacy of *L. brevis* CGMCC 21249?

While pasteurized forms of some *L. brevis* strains may retain certain immunomodulatory effects, live bacteria are generally preferred for full probiotic benefits, as survival through the GI tract is critical.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC11985112/ – This randomized controlled trial investigated *L. brevis* CD2's effect on oral biofilm acidogenicity in adults over 28 days. It found modulation of acid production but no significant changes in total viable bacteria, with trends in mutans streptococci levels. The study's moderate quality is limited by its small sample size and the use of a different *L. brevis* strain (CD2) not CGMCC 21249, focusing on oral rather than gut health.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11234635/ – This in vitro and ex vivo study used cell lines (Caco-2, RAW264.7) to examine *L. brevis* IBRC-M10790. It demonstrated significant reduction in pro-inflammatory cytokines and increased tight junction protein expression, with even pasteurized forms showing efficacy. While providing high mechanistic insight into immunomodulation and gut barrier enhancement, its in vitro nature and use of a different strain limit direct clinical relevance for CGMCC 21249.
https://d-nb.info/1174662220/34 – This laboratory study focused on bacterial cultures to identify the glutamate decarboxylase (GAD) system's critical role in acid resistance for *L. brevis* strains. It elucidated a key survival mechanism for the bacteria in acidic environments. Although not a clinical study and not specific to CGMCC 21249, its findings are indirectly relevant to the clinical efficacy of *L. brevis* by explaining its ability to survive passage through the GI tract.